On August 19, Twist Bioscience Corp rose 5.65% in pre-market trading to $122.66/share, with turnover of $1.5723 million. The stock closed the prior session down 6.68% at $116.10, and the pre-market move represents a notable recovery.

The rebound is supported by the company's fiscal Q3 earnings released on August 3, which showed revenue of $118.4 million, beating the consensus estimate of $114.5 million. More importantly, management issued Q4 revenue guidance of $123 million to $124 million, significantly above the FactSet estimate of $117.4 million. As a core DNA synthesis supplier within the AI-driven drug discovery value chain, the company's protein solutions business has demonstrated strong growth momentum. The recent completion of a $300 million equity offering to expand production capacity further reinforces the improving fundamental outlook, providing a catalyst for a technical bounce following the prior session's steep decline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)